Biofrontera Begin Period Cash Flow vs Capital Expenditures Analysis

BFRI Stock  USD 0.90  0.09  9.09%   
Biofrontera financial indicator trend analysis is way more than just evaluating Biofrontera prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biofrontera is a good investment. Please check the relationship between Biofrontera Begin Period Cash Flow and its Capital Expenditures accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.

Begin Period Cash Flow vs Capital Expenditures

Begin Period Cash Flow vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biofrontera Begin Period Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have pay attention.
The correlation between Biofrontera's Begin Period Cash Flow and Capital Expenditures is -0.8. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Biofrontera, assuming nothing else is changed. The correlation between historical values of Biofrontera's Begin Period Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Biofrontera are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Begin Period Cash Flow i.e., Biofrontera's Begin Period Cash Flow and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

-0.8
Relationship DirectionNegative 
Relationship StrengthSignificant

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Biofrontera to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Biofrontera operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most indicators from Biofrontera's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biofrontera current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.As of now, Biofrontera's Tax Provision is increasing as compared to previous years. The Biofrontera's current Issuance Of Capital Stock is estimated to increase to about 8.8 M, while Selling General Administrative is projected to decrease to under 34.7 M.
 2021 2022 2023 2024 (projected)
Depreciation And Amortization540K1.2M1.1M1.5M
Interest Income16K175K168K90.6K

Biofrontera fundamental ratios Correlations

-0.610.150.630.70.420.60.28-0.74-0.630.10.740.950.920.87-0.180.80.410.39-0.48-0.770.670.71-0.370.80.26
-0.610.67-0.35-0.98-0.29-0.96-0.520.960.85-0.54-0.33-0.49-0.56-0.450.47-0.41-0.11-0.690.940.77-0.66-0.90.95-0.52-0.62
0.150.670.15-0.54-0.03-0.65-0.330.490.54-0.680.340.280.210.320.560.340.32-0.510.720.23-0.32-0.460.810.18-0.5
0.63-0.350.150.47-0.270.530.81-0.34-0.660.430.170.70.560.46-0.370.370.830.75-0.46-0.090.290.71-0.280.780.74
0.7-0.98-0.540.470.240.950.58-0.97-0.840.460.410.610.670.57-0.40.530.270.7-0.93-0.780.610.92-0.910.670.64
0.42-0.29-0.03-0.270.240.09-0.51-0.48-0.05-0.320.740.160.490.520.290.49-0.61-0.150.04-0.720.740.14-0.04-0.14-0.36
0.6-0.96-0.650.530.950.090.69-0.88-0.950.710.170.520.50.36-0.640.290.280.83-0.98-0.610.620.95-0.940.580.77
0.28-0.52-0.330.810.58-0.510.69-0.38-0.710.67-0.190.360.250.13-0.510.080.730.89-0.720.030.10.75-0.610.620.96
-0.740.960.49-0.34-0.97-0.48-0.88-0.380.76-0.31-0.58-0.6-0.74-0.660.26-0.62-0.08-0.570.830.9-0.72-0.860.84-0.57-0.47
-0.630.850.54-0.66-0.84-0.05-0.95-0.710.76-0.81-0.09-0.55-0.46-0.30.76-0.19-0.34-0.890.90.48-0.68-0.950.8-0.56-0.81
0.1-0.54-0.680.430.46-0.320.710.67-0.31-0.81-0.50.06-0.15-0.31-0.95-0.410.20.8-0.720.040.340.63-0.640.140.78
0.74-0.330.340.170.410.740.17-0.19-0.58-0.09-0.50.640.890.940.480.940.01-0.07-0.05-0.790.520.3-0.050.46-0.2
0.95-0.490.280.70.610.160.520.36-0.6-0.550.060.640.870.82-0.170.780.630.33-0.43-0.620.420.63-0.30.920.27
0.92-0.560.210.560.670.490.50.25-0.74-0.46-0.150.890.870.990.150.950.370.32-0.39-0.790.580.65-0.320.780.22
0.87-0.450.320.460.570.520.360.13-0.66-0.3-0.310.940.820.990.30.990.320.17-0.25-0.770.490.52-0.210.730.07
-0.180.470.56-0.37-0.40.29-0.64-0.510.260.76-0.950.48-0.170.150.30.41-0.2-0.640.640.01-0.33-0.530.54-0.17-0.6
0.8-0.410.340.370.530.490.290.08-0.62-0.19-0.410.940.780.950.990.410.310.07-0.21-0.750.380.43-0.180.710.0
0.41-0.110.320.830.27-0.610.280.73-0.08-0.340.20.010.630.370.32-0.20.310.43-0.30.12-0.230.4-0.140.830.54
0.39-0.69-0.510.750.7-0.150.830.89-0.57-0.890.8-0.070.330.320.17-0.640.070.43-0.8-0.180.510.89-0.70.460.97
-0.480.940.72-0.46-0.930.04-0.98-0.720.830.9-0.72-0.05-0.43-0.39-0.250.64-0.21-0.3-0.80.53-0.47-0.90.98-0.55-0.78
-0.770.770.23-0.09-0.78-0.72-0.610.030.90.480.04-0.79-0.62-0.79-0.770.01-0.750.12-0.180.53-0.71-0.590.57-0.46-0.04
0.67-0.66-0.320.290.610.740.620.1-0.72-0.680.340.520.420.580.49-0.330.38-0.230.51-0.47-0.710.68-0.440.180.29
0.71-0.9-0.460.710.920.140.950.75-0.86-0.950.630.30.630.650.52-0.530.430.40.89-0.9-0.590.68-0.820.680.82
-0.370.950.81-0.28-0.91-0.04-0.94-0.610.840.8-0.64-0.05-0.3-0.32-0.210.54-0.18-0.14-0.70.980.57-0.44-0.82-0.43-0.69
0.8-0.520.180.780.67-0.140.580.62-0.57-0.560.140.460.920.780.73-0.170.710.830.46-0.55-0.460.180.68-0.430.48
0.26-0.62-0.50.740.64-0.360.770.96-0.47-0.810.78-0.20.270.220.07-0.60.00.540.97-0.78-0.040.290.82-0.690.48
Click cells to compare fundamentals

Biofrontera Account Relationship Matchups

Currently Active Assets on Macroaxis

When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.16
Revenue Per Share
11.573
Quarterly Revenue Growth
0.34
Return On Assets
(0.40)
Return On Equity
(1.49)
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.